title: Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars.
abstract: Human epidermal growth factor receptor 2-positive (HER2+) breast cancer comprises approximately 15%-20% of all breast cancers and is associated with a poor prognosis. The introduction of anti-HER2 therapy has significantly improved clinical outcomes for patients with HER2+ breast cancer, and multiple HER2-directed agents (ie, trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine [T-DM1]) are approved for clinical use in various settings. The treatment landscape for patients with HER2+ breast cancer is continuing to evolve. While novel agents and therapeutic strategies are emerging, biologic therapies, particularly trastuzumab, are likely to remain a mainstay of treatment. However, access issues create barriers to the use of biologics, and there is evidence for underuse of trastuzumab worldwide. A biosimilar is a biologic product that is highly similar to a licensed biologic in terms of product safety and effectiveness. Biosimilars of trastuzumab are in development and may soon become available. The introduction of biosimilars may improve access to anti-HER2 therapies by providing additional treatment options and lower-cost alternatives. Because HER2-targeted drugs may be administered for extended periods of time and in combination with other systemic therapies, biosimilars have the potential to result in significant savings for healthcare systems. Herein we review current and emerging treatment options for, and discuss the possible role of biosimilars in, treating patients with HER2+ breast cancer.
authors.affiliation: Sana Klinikum Offenbach, Starkenburgring 66, D-63069 Offenbach, Germany. Electronic address: christian.jackisch@sana.de.
authors.forename: Christian
authors.initials: C
authors.lastname: Jackisch
authors.affiliation: Meharry Medical College, 1005 Dr. D.B. Todd Jr. Blvd., Nashville, TN 37208-3501, USA. Electronic address: plammers@mmc.edu.
authors.forename: Philip
authors.initials: P
authors.lastname: Lammers
authors.affiliation: Pfizer Inc., 235 East 42nd Street, New York, NY 10017-5755, USA. Electronic address: ira.jacobs@pfizer.com.
authors.forename: Ira
authors.initials: I
authors.lastname: Jacobs
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D059451:Biosimilar Pharmaceuticals / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000187:drug effects*; D000068878:Trastuzumab / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D059451:Biosimilar Pharmaceuticals; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human
keywords: Anti-HER2 therapy; Biosimilars; HER2-Positive breast cancer; Trastuzumab